Hiroyuki Okimura

Hiroyuki Okimura

Auto-generated profile, based on publicly available information

Hiroyuki Okimura

Department of Obstetrics and Gynecology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
HOHiroyuki Okimura
Hiroyuki Okimura
YTYukiko Tanaka
Yukiko Tanaka
MFMaya Fujii
Maya Fujii
KSKoki Shimura
Koki Shimura
EMEiko Maeda
Eiko Maeda
JKJo Kitawaki
Jo Kitawaki

5 February 2018 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
HOHiroyuki Okimura
Hiroyuki Okimura
HTHiroshi Tatsumi
Hiroshi Tatsumi
FIFumitake Ito
Fumitake Ito
SYSuguru Yamashita
Suguru Yamashita
TKTetsuya Kokabu
Tetsuya Kokabu
JKJo Kitawaki
Jo Kitawaki

3 April 2025 in Human Reproduction
Verified
Journal Article
Closed access
EMEiko Maeda
Eiko Maeda
HOHiroyuki Okimura
Hiroyuki Okimura
YTYukiko Tanaka
Yukiko Tanaka
MFMaya Fujii
Maya Fujii
YTYosuke Tarumi
Yosuke Tarumi
JKJo Kitawaki
Jo Kitawaki
STUDY QUESTION: Does the restoration of regulatory T cells (Tregs) suppress the progression of endometriosis? SUMMARY ANSWER: Adoptive transfer of Tregs suppresses the progression of endometriosis and reduces the levels of helper T (Th)-cell-related and proinflammatory cytokines in mice. WHAT IS KNOWN ALREADY: Endometriosis is a chronic inflammatory gynecological disease, which involves multiple immune components. Activated Treg counts decrease in the endometrioma and endometrium of patients with endometriosis, and depletion of Tregs exacerbates endometriosis in mice. STUDY DESIGN, SIZE, DURATION: We evaluated the effects of adoptive transfer of Tregs on the progression of endometriosis in mice. We used Foxp3tm3Ayr/J (Foxp3DTR) mice with temporarily ablated Tregs by injecting diphtheria toxin to develop an endometriosis model, which was generated by ovariectomy, estradiol administration and transplantation of uterine fragments from donor mice. Foxp3DTR mice were randomly divided into Treg adoptive transfer (n = 12) and control (n = 11) groups. Tregs were isolated from lymph nodes and spleens of wild-type (WT) mice and were adoptively transferred into mice that were temporarily Treg-depleted. Control mice were injected with vehicle. Treg adoptive transfer was performed on the day of uterine implantation, and a second adoptive transfer was performed after 14 days. Mice were euthanized 28 days after uterine implantation, and blood, peritoneal fluid, spleen, and endometriosis-like lesion samples were collected. PARTICIPANTS/MATERIALS, SETTING, METHODS: Foxp3DTR mice were intravenously injected with Tregs isolated from WT mice. The number, total weight, and total volume of the endometriosis-like lesions were evaluated on Day 28 following implantation of uterine fragments. The proportion of Tregs in endometriosis-like lesions, ascites, and peripheral blood was analyzed by flow cytometry. Inflammation in lesions and serum was examined using real-time PCR and ELISA. MAIN RESULTS AND THE ROLE OF CHANCE: Injection of Tregs increased their total count and decreased the number (P < 0.0001), weight (P = 0.0021), and volume (P = 0.0010) of endometriosis-like lesions in Foxp3DTR Treg-depleted mice. Furthermore, injection of Tregs decreased the mRNA expression of Th 1-, 2-, and 17-related cytokines, including interferon gamma (P = 0.0101), interleukin (IL)-4 (P = 0.0051), and IL-17 (P = 0.0177), as well as the levels of the proinflammatory cytokine IL-6 (P = 0.0002), in endometriosis-like lesions of Foxp3DTR Treg-depleted mice. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Treg-related immune mechanisms in mice may not precisely reflect those in humans. WIDER IMPLICATIONS OF THE FINDINGS: Restoration of Tregs may be a useful therapeutic strategy for inhibiting the progression of endometriosis in cases where the decrease in the Treg population is an exacerbating factor. STUDY FUNDING/COMPETING INTEREST(S): This study was partially supported by the Grants-in-Aid for Scientific Research (grant numbers 18K16808 and 20K22983) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The sponsor had no role in the study design, collection, analysis and interpretation of data, writing of the report, and decision to submit the article for publication. The authors have no conflicts of interest to disclose.

30 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FIFumitake Ito
Fumitake Ito
TMTaisuke Mori
Taisuke Mori
YTYosuke Tarumi
Yosuke Tarumi
HOHiroyuki Okimura
Hiroyuki Okimura
HKHisashi Kataoka
Hisashi Kataoka
JKJo Kitawaki
Jo Kitawaki
The adhesion of monocytes to endothelial cells, which is mediated by adhesion molecules, plays a crucial role in the onset of atherosclerosis. Conjugated equine estrogen, which is widely used for estrogen-replacement therapy, contains both estrone sulfate and various nonhuman estrogens, including equilin. To investigate the association between various estrogen types and atherosclerosis risk, we examined their effect on adhesion-molecule expression in human umbilical vein endothelial cells (HUVECs). In estrogen-treated HUVECs, the mRNA and protein expression levels of adhesion molecules were quantified by real-time polymerase chain reaction and enzyme immunoassay. Additionally, a flow-chamber system was used to assess the effects of estrogens on the adherence of U937 monocytoid cells to HUVECs. Equilin, but not 17β-estradiol (E2) or other types of estrogen, significantly increased the mRNA (P < 0.01) and protein (P < 0.05) expression of the adhesion molecules E-selectin and intercellular adhesion molecule-1 as compared with levels in controls. Equilin treatment increased the adherence of U937 monocytoid cells to HUVECs relative to the that in the control (P < 0.05), decreased estrogen receptor (ER)β expression, and increased the expression of proteins involved in nuclear factor kappa-B (NF-κB) activation relative to levels in controls. Furthermore, the accumulation of NF-κB subunit p65 in HUVEC nuclei was promoted by equilin treatment. By contrast, E2 treatment neither increased the number of adhered monocytoid cells to HUVECs nor altered the expression of ERβ or NF-κB-activating proteins. Our findings suggest that in terms of the adhesion of monocytes at the onset of atherosclerosis, E2 may be preferable for estrogen-replacement therapy. Further studies comparing equilin treatment with that of E2 are needed to investigate their differential impacts on atherosclerosis.

1 April 2022 in Journal of Adolescent and Young Adult Oncology
Verified
Journal Article
Closed access
TMTadashi Maezawa
Tadashi Maezawa
NSNao Suzuki
Nao Suzuki
HTHiroki Takeuchi
Hiroki Takeuchi
CKChikako Kiyotani
Chikako Kiyotani
KAKeishiro Amano
Keishiro Amano
KMKimikazu Matsumoto
Kimikazu Matsumoto
Purpose: We conducted a questionnaire survey in 15 pediatric oncology hospitals in Japan to better understand the current status of fertility preservation in childhood and adolescents. Methods: The survey period was from September 2020 to December 2020. We mailed questionnaires to 64 departments involved in pediatric cancer treatments at the 15 hospitals. The primary outcomes were the timing of providing explanations on fertility preservation, presence of health care provider while providing explanations, cooperation between medical staff, and cooperation between hospitals. Results: The response rate was 100% (64/64). Regarding the time at which this information was provided, 79.6% of patients (43/54) received it before cancer treatment; 5.6% (3/54), after remission; and 14.8% (8/54), both time points. Nurses were mostly in attendance (70%) when oncologists provided information to patients. Nine (60%) hospitals did not have a reproductive department. Among these, 28.6% of the respondents referred patients to a reproductive facility that performed fertility preservation. Providing information about fertility preservation was challenging owing to the shortage of specific explanatory materials (35.1%) and the lack of cooperation between pediatric oncologists and reproductive endocrinologists (24.6%). Conclusion: Based on this survey, educational activities regarding fertility preservation centered on pediatric oncologists and nurses are needed. Furthermore, a system for providing explanatory materials for fertility preservation and encouraging cooperation at the physician and hospital levels is also needed (IRB No. H2020-111).

29 October 2024 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Open access
KYKaori Yoriki
Kaori Yoriki
YIYuko Izumi
Yuko Izumi
YTYosuke Tarumi
Yosuke Tarumi
HOHiroyuki Okimura
Hiroyuki Okimura
EMEiko Maeda
Eiko Maeda
TMTaisuke Mori
Taisuke Mori
Ovarian carcinosarcoma in hereditary breast and ovarian cancer syndrome is rare. A 43‐year‐old woman with a family history of prostate and uterine or ovarian cancer had an 8‐cm mass in the right ovary. Although computed tomography suggested peritoneal dissemination to the Douglas pouch, she wanted to preserve her fertility; therefore, she underwent a right salpingo‐oophorectomy. Histopathological diagnosis was carcinosarcoma consisting of high‐grade serous carcinoma and sarcomatous components, including cartilage. Three weeks later, she underwent radical surgery. The disease was classified as advanced stage IIIB (FIGO 2014). A germline BRCA2 pathogenic variant was identified. After postoperative adjuvant chemotherapy, maintenance therapy with a poly(adenosine diphosphate‐ribose) polymerase (PARP) inhibitor was continued for 25 months without recurrence. A detailed examination of a mass in her left breast at her first visit revealed a ductal carcinoma in situ. PARP inhibitors may be effective as maintenance therapy for advanced ovarian carcinosarcoma with germline BRCA mutations.